Fatiu AbiolaArogundade NigeriaObafemi Awolowo University Teaching Hospitals Complex/ National Postgraduate Medical College of Nigeria

Back

Institution

Day 1 - Sunday April 14, 2024

Time	Session

09:00 10:30	APOL1 Targeted Therapies: Who to Test and Which Disease to Treat? SK100 Fatiu AbiolaArogundade Chairperson fatiu3@yahoo.comNigeriaObafemi Awolowo University Teaching Hospitals Complex/ National Postgraduate Medical College of Nigeria FernandaSales Luiz Vianna Chairperson fslvianna@gmail.comBrazilUniversidade Federal do Rio Grande do Sul OpeyemiOlabisi Chairperson opeyemi.olabisi@duke.eduUnited StatesDuke University School of Medicine Ethical Aspects of Race-based Genetic Testing AnaIltis Speaker iltisas@wfu.eduUnited StatesWake Forest University Contribution of ApoL1 Risk Genotype to HIVAN SaraladeviNaicker Speaker Saraladevi.Naicker@wits.ac.zaSouth AfricaUniversity of the Witwatersrand Contribution of APOL1 Risk Alleles to Kidney Disease in West Africa DwomoaAdu Speaker dwoms@blueyonder.co.ukGhanaUniversity of Ghana Medical School Targeting ApoL1: A 12-Year Journey from Genetic Discovery to Phase 2 Trials OgoEgbuna Speaker ogo_egbuna@vrtx.comUnited StatesVertex Pharmaceuticals Inc Q and A Hall C2

Time

Session

09:00

10:30

APOL1 Targeted Therapies: Who to Test and Which Disease to Treat?

SK100

Fatiu AbiolaArogundade Chairperson fatiu3@yahoo.comNigeriaObafemi Awolowo University Teaching Hospitals Complex/ National Postgraduate Medical College of Nigeria

FernandaSales Luiz Vianna Chairperson fslvianna@gmail.comBrazilUniversidade Federal do Rio Grande do Sul

OpeyemiOlabisi Chairperson opeyemi.olabisi@duke.eduUnited StatesDuke University School of Medicine

Ethical Aspects of Race-based Genetic Testing

AnaIltis Speaker iltisas@wfu.eduUnited StatesWake Forest University
Contribution of ApoL1 Risk Genotype to HIVAN

SaraladeviNaicker Speaker Saraladevi.Naicker@wits.ac.zaSouth AfricaUniversity of the Witwatersrand
Contribution of APOL1 Risk Alleles to Kidney Disease in West Africa

DwomoaAdu Speaker dwoms@blueyonder.co.ukGhanaUniversity of Ghana Medical School
Targeting ApoL1: A 12-Year Journey from Genetic Discovery to Phase 2 Trials

OgoEgbuna Speaker ogo_egbuna@vrtx.comUnited StatesVertex Pharmaceuticals Inc
Q and A

Hall C2